Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia von Cortes, Jorge, Quintás‐Cardama, Alfonso, Jones, Dan, Ravandi, Farhad, Garcia‐Manero, Guillermo, Verstovsek, Srdan, Koller, Charles, Hiteshew, Jody, Shan, Jenny, O'Brien, Susan, Kantarjian, Hagop

Volltext

Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia: A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegyl... von CORTES, Jorge, QUINTAS-CARDAMA, Alfonso, KANTARJIAN, Hagop, JONES, Dan, RAVANDI, Farhad, GARCIA-MANERO, Guillermo, VERSTOVSEK, Srdan, KOLLER, Charles, HITESHEW, Jody, SHAN, Jenny, O'BRIEN, Susan

Volltext

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib von Ayoubi, Mohamad, Kantarjian, Hagop M., Wierda, William, Ferrajoli, Alessandra, Hiteshew, Jody, Estrov, Zeev, Cortes-Franco, Jorge

Volltext